Please login to the form below

Not currently logged in

SMC approves Biogen’s Vumerity for patients with multiple sclerosis

The new, at-home oral treatment has been developed for adults in Scotland living with relapsing-remitting multiple sclerosis


Biogen’s Vumerity (diroximel fumarate) has been approved by the Scottish Medicines Consortium (SMC) as an oral treatment for adults with relapsing-remitting multiple sclerosis (RRMS).

RRMS is the most common type of multiple sclerosis (MS) and there are 15,000 people with MS in Scotland. Vumerity is a new option for people diagnosed with RRMS as it offers a significantly improved gastrointestinal tolerability profile, alongside improved effectiveness and safety markers when compared to existing treatments.

David Martin, CEO of the MS Trust, David Martin, said: “Effective treatments that fit into daily life can help people live a life with MS that is not defined by MS. People living with MS can be confident in the established efficacy of this new oral treatment that has fewer stomach problems to manage. This can mean that they don’t have to factor their medication in relation to mealtimes.”

The SMC based its decision on results from pivotal phase 3 trials – EVOLVE-MS-1 and EVOLVE-MS-2 – which compared diroximel fumarate and dimethyl fumarate with both demonstrating similar effectiveness in safety profiles.

With this latest decision from the SMC, Biogen is able to reinforce its existing MS portfolio and commitments to developing new oral treatments for the MS community.

Dr Mihaela Vlaicu, head of medical affairs at Biogen UK and Ireland, said: “The SMC approval of diroximel fumarate [helps us] to introduce new therapies that can individualise treatment options and improve MS care.”

Dr Martin Duddy, consultant Neurology at the Royal Victoria Infirmary, Newcastle, said: “Disease-modifying therapies can successfully decrease the chances of relapses and improve the quality of life for those living with MS. The challenge can be keeping people on these effective treatments long-term; therefore, new efficacious options with improved tolerability profiles such as diroximel fumarate, are welcomed to help people start and stay on treatment.”

Article by
Fleur Jeffries

9th February 2022

From: Regulatory



Subscribe to our email news alerts

Featured jobs


Add my company

Accession was a born from a passion and a vision. A passion to harness the power of market access to...

Latest intelligence

Neil Thompson
How AI is finally helping rare diseases gain more than just attention
By Neil Thompson...
Is communication failing us?
Compelling people to care in a world oversaturated with news and information...
Are your field teams ready to excel in the new era?
A qualitative research approach to help you critically assess post-pandemic learnings and ignite the potential of meaningful interactions with HCPs....